Feb 07, 2022 4:01 pm EST Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Jan 26, 2022 4:30 pm EST Atara Biotherapeutics Enters Strategic Manufacturing Partnership with Fujifilm
Jan 24, 2022 11:13 am EST New Landmark Nature Study Provides Long-Sought Mechanistic Link Between EBV and Multiple Sclerosis, Extending Findings from Recent Paper in Science That Identified EBV as the Leading Cause of Multiple Sclerosis
Jan 10, 2022 8:30 am EST Atara Biotherapeutics to Present Recent Progress and Key Upcoming Catalysts at the 40th Annual J.P. Morgan Healthcare Conference
Jan 07, 2022 4:01 pm EST Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan 05, 2022 4:01 pm EST Atara Biotherapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
Dec 13, 2021 7:15 pm EST Atara Biotherapeutics Announces Positive Results from Pivotal Phase 3 Trial (ALLELE) of Tab-cel® at the 63rd American Society of Hematology (ASH) Annual Meeting
Dec 09, 2021 8:00 am EST Atara Biotherapeutics Announces Preliminary Results for ATA2271, a Next-Generation Autologous Mesothelin-targeted CAR T-cell Therapy for Solid Tumors, at ESMO Immuno-Oncology Congress 2021
Dec 03, 2021 4:01 pm EST Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 30, 2021 8:30 am EST European Medicines Agency (EMA) Validates Atara Biotherapeutics' Marketing Authorization Application for Tabelecleucel for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease